Covaxin manufacturer Bharat Biotech has received approval from Drugs Controller General of India (DCGI) for emergency use of its vaccine for children aged between 12-18 years.
Covaxin is now the second vaccine cleared for use for children in India. In August, The Drugs Controller General of India (DCGI) gave approval for emergency-use authorization of Zydus Cadila’s ZyCoV-D vaccine, the Union Ministry of Science and Technology said.
The world’s first and India’s indigenously developed DNA-based vaccine for COVID-19 will be administered in humans including children and adults 12 years and above, the ministry said.
This vaccine is a whole virion inactivated vaccine against Covid, developed in partnership with ICMR and NIV.
Bharat Biotech recently submitted the phase 3 clinical trial application to the Drugs Controller General of India (DCGI) to get approval for the booster dose of its intranasal Covid vaccine named ‘BBV154’.
